tamoxifen,triptorelin,exemestane
azurity pharmaceuticals,astrazeneca,pfizer
[]
 the interesting re-analysis of big 1-98, soft and text trials (5 yrs adjuv ai vs tam) in pre/postmenopausal high risk hr+/her2- early bc pts showed that the treatment benefit emerged already by 2 yrs and were indicative of those over 5 yrs. #bcareporter #asco22 